Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      3 experts are featured in this series.
      Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
      Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
      Angiogenesis 2025: The global forecast for AI-driven home OCT
      3 experts are featured in this series.
      Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
      3 experts are featured in this series.
      Perspectives on the Usefulness of Real-world Data
      3 experts are featured in this series.
      Safety Profile of New Therapies
      3 experts are featured in this series.
      Outcomes with Raricimab and Choosing Between the New Therapies
      3 experts are featured in this series.
      Faricimab Molecular Design and Role of Ang-2
      3 experts are featured in this series.
      Patient Selection for Aflibercept 8 mg
      3 experts are featured in this series.
      Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg
      3 experts are featured in this series.
      Significance of the Higher Molar Dose of Aflibercept 8 mg
      Related Content
      Two boxes, labeled "yes" and "no." There is a red checkmark in the "no" box. Concept portraying an ophthalmic clinical trial which does not meet its endpoint. Image credit: ©Matthew Benoit – stock.adobe.com

      Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports

      Martin David Harp
      March 24th 2025
      Article

      The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

      Rows of medical syringes in sanitary packaging. Concept image for aflibercept intravitreal eye injection. ©Titolino – stock.adobe.com

      Study examines real-world treat-and-extend outcomes and background factors of macular atrophy

      Lynda Charters
      March 21st 2025
      Article

      The study demonstrated that the number of injections needed gradually decreased during the follow-up period

      A blue hazard sign, an exclamation point (!) inside a triangle, to communicate the risks of misdiagnosing geographic atrophy and age-related macular degeneration. Image credit: ©jcsnb – stock.adobe.com

      Researchers raise awareness of macular pathologies which mimic AMD and GA

      Lynda Charters
      March 20th 2025
      Article

      Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs

      A person in scrubs holds their hand outstretched toward the camera. A digital overlay gives the impression that the doctor or clinician is offering information about the future of eye care and retinal health. Image credit: ©sdecoret – stock.adobe.com

      Advanced therapies in neovascular AMD and DMO: Experts weigh in

      Hattie Hayes
      March 12th 2025
      Article

      A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

      An image showing the degeneration of neuron cells. Image credit: ©Corona Borealis – stock.adobe.com

      Cognition Therapeutics announces publication reviewing potential of zervimesine (CT1812) in dry AMD

      Jordana Joy
      March 3rd 2025
      Article

      One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom

      A crystal ball sits on a small platform, surrounded by misty fog. ©alexkich – stock.adobe.com

      Retinal biomarkers in OCT imaging may have predictive applications for nAMD

      Lynda Charters
      February 17th 2025
      Article

      The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers

      © 2025 MJH Life Sciences

      All rights reserved.